You asked me which *data* formed the basis, not about my interpretation of the performance data, and all the causes of progress. If EPO was the only changing variable over three decades, you might have a point. I don't really want to rehash the performance thread -- everything you could possibly say has been said over there, and addressed. But just the same, if you read the rest of that thread, you will find how I interpreted the data. Since EPO was a global drug, available everywhere, widely abused, and globally undetectable, and the performance success was local to athletes from two regions in Africa, even when they were permanently based in countries with testing, I argued that: - EPO is a bad explanation for the success of Africans - the small progress of non-Africans (0.3% to 0.8%) representing 85% of the world population over three decades, is a better indication - the regional success of North Africans and East Africans are best explained by other regional factors unique to Africans and Africa
Survey Says.... wrote:
rekrunner wrote:
For a detailed look the data I used, and how that shapes my opinions, please re-read the first three posts here:
The only distance you have for "not more than 1%" is the 1500 (which is actually 1.1% by your calculations). You have the EAs at 1.6% (3000), 2.3% (SC), 2.6% (5000), 3.0% (10000) and 3.2% for the marathon.
Other than the ~1% for the 1500 - where is it "not more than 1%" for the other distances? Are you misinterpreting your own data?